Noscendo is thrilled to share that our DISQVER® platform has been highlighted in the World Health Organization’s recent report.
“Landscape analysis of commercially available and pipeline in vitro diagnostics for fungal priority pathogens” presents the first World Health Organization (WHO) analysis of commercially available diagnostic products and pipeline diagnostic products for invasive fungal diseases (IFDs). It mentions DISQVER® on page 16: "Only one commercially available NGS platform approved for clinical use for diagnosis of IFDs was found – DISQVER® (Noscendo GmbH, Germany)."
This recognition underscores the significant impact of DISQVER® in the realm of infectious disease diagnostics. By leveraging metagenomic next-generation sequencing (mNGS), DISQVER® enables the rapid and reliable detection of over 16,000 microbial species, including more than 1,500 pathogens, from a single patient sample.
The WHO’s acknowledgment aligns with recent studies demonstrating DISQVER®’s effectiveness in detecting pathogens in patients with suspected infections, even when traditional blood cultures remain negative.
As we continue to advance our mission of redefining pathogen detection, this mention by the WHO serves as a testament to the dedication of our team and the transformative potential of DISQVER® in clinical diagnostics.